Delayed-type hypersensitivity response to high doses of adenoviral vectors

Thomas J. Russi, Edward A. Hirschowitz, Ronald Crystal

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The present study evaluates the hypothesis that delayed-type hypersensitivity (DTH) contributes to the inflammatory reaction observed when high-dose adenoviral (Ad) vectors are administered to a previously immunized animal. Immunocompetent C57BL/6 mice immunized intraperitoneally with 109 pfu AdCMV. Null [an E1-, E3- Ad vector with a cytomegalovirus (CMV) promoter but no transgene] and challenged intradermally to the footpad with the same vector demonstrated significant footpad swelling 24 hr after challenge with 109 pfu, but not with a lower dose. Footpad histology revealed a mononuclear-granulocytic cellular infiltrate typical of that seen in DTH. Evaluation of the same doses of vector in immunodeficient mice nu/nu and RAG-2- on the C57BL/6 background, and nu/nu and severe combined immunodeficiency (SCID) on the BALB/c background demonstrated suppression of footpad swelling. However, the footpad response remained intact inβ2-microglobulin deficient (β2-m-) mice, suggesting minimal or no role of major histocompatibility complex (MHC) class I-mediated mechanisms for the region of localized inflammation. Challenge with an Ad expressing the interleukin-2 cDNA to immunized C57BL/6 mice demonstrated augmented footpad swelling response. Finally, pretreatment with cyclosporin resulted in a 69% inhibition of the response compared to controls, whereas other immunosuppressants (cyclophosphamide, methotrexate, and hydrocortisone) had no inhibitory effect. These findings provide further insight into the dynamic interplay of immune processes ultimately leading to inflammation when high-dose Ad vectors are administered to a target organ.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalHuman Gene Therapy
Volume8
Issue number3
DOIs
Publication statusPublished - 10 Feb 1997
Externally publishedYes

Fingerprint

Delayed Hypersensitivity
Inbred C57BL Mouse
Inflammation
Severe Combined Immunodeficiency
Immunosuppressive Agents
Major Histocompatibility Complex
Cytomegalovirus
Transgenes
Methotrexate
Cyclophosphamide
Cyclosporine
Interleukin-2
Hydrocortisone
Histology
Complementary DNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Delayed-type hypersensitivity response to high doses of adenoviral vectors. / Russi, Thomas J.; Hirschowitz, Edward A.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 8, No. 3, 10.02.1997, p. 323-330.

Research output: Contribution to journalArticle

Russi, Thomas J. ; Hirschowitz, Edward A. ; Crystal, Ronald. / Delayed-type hypersensitivity response to high doses of adenoviral vectors. In: Human Gene Therapy. 1997 ; Vol. 8, No. 3. pp. 323-330.
@article{a726e71e6c494fb38d61d149d1717916,
title = "Delayed-type hypersensitivity response to high doses of adenoviral vectors",
abstract = "The present study evaluates the hypothesis that delayed-type hypersensitivity (DTH) contributes to the inflammatory reaction observed when high-dose adenoviral (Ad) vectors are administered to a previously immunized animal. Immunocompetent C57BL/6 mice immunized intraperitoneally with 109 pfu AdCMV. Null [an E1-, E3- Ad vector with a cytomegalovirus (CMV) promoter but no transgene] and challenged intradermally to the footpad with the same vector demonstrated significant footpad swelling 24 hr after challenge with 109 pfu, but not with a lower dose. Footpad histology revealed a mononuclear-granulocytic cellular infiltrate typical of that seen in DTH. Evaluation of the same doses of vector in immunodeficient mice nu/nu and RAG-2- on the C57BL/6 background, and nu/nu and severe combined immunodeficiency (SCID) on the BALB/c background demonstrated suppression of footpad swelling. However, the footpad response remained intact inβ2-microglobulin deficient (β2-m-) mice, suggesting minimal or no role of major histocompatibility complex (MHC) class I-mediated mechanisms for the region of localized inflammation. Challenge with an Ad expressing the interleukin-2 cDNA to immunized C57BL/6 mice demonstrated augmented footpad swelling response. Finally, pretreatment with cyclosporin resulted in a 69{\%} inhibition of the response compared to controls, whereas other immunosuppressants (cyclophosphamide, methotrexate, and hydrocortisone) had no inhibitory effect. These findings provide further insight into the dynamic interplay of immune processes ultimately leading to inflammation when high-dose Ad vectors are administered to a target organ.",
author = "Russi, {Thomas J.} and Hirschowitz, {Edward A.} and Ronald Crystal",
year = "1997",
month = "2",
day = "10",
doi = "10.1089/hum.1997.8.3-323",
language = "English",
volume = "8",
pages = "323--330",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Delayed-type hypersensitivity response to high doses of adenoviral vectors

AU - Russi, Thomas J.

AU - Hirschowitz, Edward A.

AU - Crystal, Ronald

PY - 1997/2/10

Y1 - 1997/2/10

N2 - The present study evaluates the hypothesis that delayed-type hypersensitivity (DTH) contributes to the inflammatory reaction observed when high-dose adenoviral (Ad) vectors are administered to a previously immunized animal. Immunocompetent C57BL/6 mice immunized intraperitoneally with 109 pfu AdCMV. Null [an E1-, E3- Ad vector with a cytomegalovirus (CMV) promoter but no transgene] and challenged intradermally to the footpad with the same vector demonstrated significant footpad swelling 24 hr after challenge with 109 pfu, but not with a lower dose. Footpad histology revealed a mononuclear-granulocytic cellular infiltrate typical of that seen in DTH. Evaluation of the same doses of vector in immunodeficient mice nu/nu and RAG-2- on the C57BL/6 background, and nu/nu and severe combined immunodeficiency (SCID) on the BALB/c background demonstrated suppression of footpad swelling. However, the footpad response remained intact inβ2-microglobulin deficient (β2-m-) mice, suggesting minimal or no role of major histocompatibility complex (MHC) class I-mediated mechanisms for the region of localized inflammation. Challenge with an Ad expressing the interleukin-2 cDNA to immunized C57BL/6 mice demonstrated augmented footpad swelling response. Finally, pretreatment with cyclosporin resulted in a 69% inhibition of the response compared to controls, whereas other immunosuppressants (cyclophosphamide, methotrexate, and hydrocortisone) had no inhibitory effect. These findings provide further insight into the dynamic interplay of immune processes ultimately leading to inflammation when high-dose Ad vectors are administered to a target organ.

AB - The present study evaluates the hypothesis that delayed-type hypersensitivity (DTH) contributes to the inflammatory reaction observed when high-dose adenoviral (Ad) vectors are administered to a previously immunized animal. Immunocompetent C57BL/6 mice immunized intraperitoneally with 109 pfu AdCMV. Null [an E1-, E3- Ad vector with a cytomegalovirus (CMV) promoter but no transgene] and challenged intradermally to the footpad with the same vector demonstrated significant footpad swelling 24 hr after challenge with 109 pfu, but not with a lower dose. Footpad histology revealed a mononuclear-granulocytic cellular infiltrate typical of that seen in DTH. Evaluation of the same doses of vector in immunodeficient mice nu/nu and RAG-2- on the C57BL/6 background, and nu/nu and severe combined immunodeficiency (SCID) on the BALB/c background demonstrated suppression of footpad swelling. However, the footpad response remained intact inβ2-microglobulin deficient (β2-m-) mice, suggesting minimal or no role of major histocompatibility complex (MHC) class I-mediated mechanisms for the region of localized inflammation. Challenge with an Ad expressing the interleukin-2 cDNA to immunized C57BL/6 mice demonstrated augmented footpad swelling response. Finally, pretreatment with cyclosporin resulted in a 69% inhibition of the response compared to controls, whereas other immunosuppressants (cyclophosphamide, methotrexate, and hydrocortisone) had no inhibitory effect. These findings provide further insight into the dynamic interplay of immune processes ultimately leading to inflammation when high-dose Ad vectors are administered to a target organ.

UR - http://www.scopus.com/inward/record.url?scp=0030879828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030879828&partnerID=8YFLogxK

U2 - 10.1089/hum.1997.8.3-323

DO - 10.1089/hum.1997.8.3-323

M3 - Article

C2 - 9048199

AN - SCOPUS:0030879828

VL - 8

SP - 323

EP - 330

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -